Intestinal permeability and appetite regulating peptides-reactive immunoglobulins in severely malnourished women with anorexia nervosa.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
08 2022
Historique:
received: 17 01 2022
revised: 07 06 2022
accepted: 24 06 2022
pubmed: 11 7 2022
medline: 5 8 2022
entrez: 10 7 2022
Statut: ppublish

Résumé

In the last decades, the role of microbiota-gut-brain axis has emerged in the regulation of eating behavior and in the pathophysiology of anorexia nervosa (AN) that remains poorly understood. Particularly, a gut-derived dysregulation of immune response has been proposed leading to immunoglobulins directed against appetite-regulating peptides. However, intestinal permeability in patients with anorexia nervosa has been poorly documented. In the present prospective case-control study, we thus compared intestinal permeability, appetite-regulating peptides and their reactive immunoglobulins measured in severely malnourished women with AN (n = 17; 28 [21-35] y; 14.9 [14.1-15.2] kg/m Patients with AN exhibited an increased urinary lactulose/mannitol ratio, both in 0-5 h (0.033 [0.013-0.116]) and 5-24 h samples (0.115 [0.029-0.582]), when compared to HV (0.02 [0.008-0.045], p = 0.0074 and 0.083 [0.019-0.290], p = 0.0174, respectively), suggesting an increased intestinal permeability. Urinary excretion of sucralose and plasma zonulin were not different. The levels of plasma total ghrelin and desacyl-ghrelin were increased in patients with AN compared to HV, whereas plasma leptin concentration was decreased. In addition, αMSH remained unchanged compared to HV. Finally, we did not observe any modification of the levels of total or free αMSH, leptin or ghrelin-reactive immunoglobulin G and M, as well as for their affinity properties. Only, a weak decrease of the dissociation constant (kd) for acyl-ghrelin-reactive IgG was observed in patients with AN (p = 0.0411). In conclusion, severely malnourished patients with AN show a higher intestinal permeability than HV without evidence of an effect on appetite regulating peptides-reactive immunoglobulins.

Sections du résumé

BACKGROUND & AIMS
In the last decades, the role of microbiota-gut-brain axis has emerged in the regulation of eating behavior and in the pathophysiology of anorexia nervosa (AN) that remains poorly understood. Particularly, a gut-derived dysregulation of immune response has been proposed leading to immunoglobulins directed against appetite-regulating peptides. However, intestinal permeability in patients with anorexia nervosa has been poorly documented.
METHODS
In the present prospective case-control study, we thus compared intestinal permeability, appetite-regulating peptides and their reactive immunoglobulins measured in severely malnourished women with AN (n = 17; 28 [21-35] y; 14.9 [14.1-15.2] kg/m
RESULTS
Patients with AN exhibited an increased urinary lactulose/mannitol ratio, both in 0-5 h (0.033 [0.013-0.116]) and 5-24 h samples (0.115 [0.029-0.582]), when compared to HV (0.02 [0.008-0.045], p = 0.0074 and 0.083 [0.019-0.290], p = 0.0174, respectively), suggesting an increased intestinal permeability. Urinary excretion of sucralose and plasma zonulin were not different. The levels of plasma total ghrelin and desacyl-ghrelin were increased in patients with AN compared to HV, whereas plasma leptin concentration was decreased. In addition, αMSH remained unchanged compared to HV. Finally, we did not observe any modification of the levels of total or free αMSH, leptin or ghrelin-reactive immunoglobulin G and M, as well as for their affinity properties. Only, a weak decrease of the dissociation constant (kd) for acyl-ghrelin-reactive IgG was observed in patients with AN (p = 0.0411).
CONCLUSIONS
In conclusion, severely malnourished patients with AN show a higher intestinal permeability than HV without evidence of an effect on appetite regulating peptides-reactive immunoglobulins.

Identifiants

pubmed: 35810568
pii: S0261-5614(22)00230-8
doi: 10.1016/j.clnu.2022.06.036
pii:
doi:

Substances chimiques

Ghrelin 0
Immunoglobulins 0
Leptin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1752-1758

Informations de copyright

Copyright © 2022 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest PD is cofounder and shareholder of TargEDys SA company, MC is shareholder of TargEDys SA company. Other authors declared no conflict of interest.

Auteurs

Sébastien Grigioni (S)

Department of Nutrition, Rouen University Hospital, CHU Rouen, France; Université de Rouen Normandie, Inserm UMR1073 « Nutrition, Inflammation and Microbiota-gut-brain Axis », Institute for Research and Innovation in Biomedicine, Rouen, France; Clinical Investigation Center CIC 1404 - Biological Resources Centre, Inserm, Rouen University Hospital, CHU Rouen, France.

Najate Achamrah (N)

Department of Nutrition, Rouen University Hospital, CHU Rouen, France; Université de Rouen Normandie, Inserm UMR1073 « Nutrition, Inflammation and Microbiota-gut-brain Axis », Institute for Research and Innovation in Biomedicine, Rouen, France; Clinical Investigation Center CIC 1404 - Biological Resources Centre, Inserm, Rouen University Hospital, CHU Rouen, France.

Philippe Chan (P)

PISSARO Proteomics Platform, HeRacLeS High-tech Research Infrastructures for Life, UMS 51 - UAR 2026, Inserm, CNRS, Université de Rouen Normandie, Rouen, France.

Charlène Guérin (C)

Department of Nutrition, Rouen University Hospital, CHU Rouen, France; Université de Rouen Normandie, Inserm UMR1073 « Nutrition, Inflammation and Microbiota-gut-brain Axis », Institute for Research and Innovation in Biomedicine, Rouen, France.

Christine Bôle-Feysot (C)

Department of Nutrition, Rouen University Hospital, CHU Rouen, France; Université de Rouen Normandie, Inserm UMR1073 « Nutrition, Inflammation and Microbiota-gut-brain Axis », Institute for Research and Innovation in Biomedicine, Rouen, France.

Julie Delay (J)

Department of Nutrition, Rouen University Hospital, CHU Rouen, France.

Guillaume Colange (G)

Department of Nutrition, Rouen University Hospital, CHU Rouen, France.

Muriel Quillard (M)

Université de Rouen Normandie, Inserm UMR1073 « Nutrition, Inflammation and Microbiota-gut-brain Axis », Institute for Research and Innovation in Biomedicine, Rouen, France; Clinical Investigation Center CIC 1404 - Biological Resources Centre, Inserm, Rouen University Hospital, CHU Rouen, France.

Aude Coquard (A)

Department of Pharmacy, Rouen University Hospital, CHU Rouen, France.

Michael Bubenheim (M)

Department of Clinical Research and Innovation, Rouen University Hospital, CHU Rouen, France.

Pierre Jésus (P)

Nutrition Unit, Limoges University Hospital, Inserm UMR 1094 Tropical Neuro-epidemiology, Limoges, France.

Marie-Pierre Tavolacci (MP)

Université de Rouen Normandie, Inserm UMR1073 « Nutrition, Inflammation and Microbiota-gut-brain Axis », Institute for Research and Innovation in Biomedicine, Rouen, France; Clinical Investigation Center CIC 1404 - Biological Resources Centre, Inserm, Rouen University Hospital, CHU Rouen, France.

Pierre Déchelotte (P)

Department of Nutrition, Rouen University Hospital, CHU Rouen, France; Université de Rouen Normandie, Inserm UMR1073 « Nutrition, Inflammation and Microbiota-gut-brain Axis », Institute for Research and Innovation in Biomedicine, Rouen, France; Clinical Investigation Center CIC 1404 - Biological Resources Centre, Inserm, Rouen University Hospital, CHU Rouen, France.

Moïse Coëffier (M)

Department of Nutrition, Rouen University Hospital, CHU Rouen, France; Université de Rouen Normandie, Inserm UMR1073 « Nutrition, Inflammation and Microbiota-gut-brain Axis », Institute for Research and Innovation in Biomedicine, Rouen, France; Clinical Investigation Center CIC 1404 - Biological Resources Centre, Inserm, Rouen University Hospital, CHU Rouen, France. Electronic address: moise.coeffier@univ-rouen.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH